Compare Stocks

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAV Camrova Resources	C$0.07 +∞	C$0.06	C$0.06 ▼ C$0.11	C$1.50M	N/A	17,375 shs	9,208 shs
NNN NNN REIT	$41.03 -0.3%	$41.41	$34.38 ▼ $44.96	$7.50B	1	1.39 million shs	1.14 million shs
PBM Psyence Biomedical	$0.84 +5.2%	$0.95	$0.51 ▼ $4.31	$7.38M	-0.22	3.61 million shs	97,058 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAV Camrova Resources	0.00%	0.00%	0.00%	0.00%	0.00%
NNN NNN REIT	+0.44%	+3.71%	-2.14%	-0.53%	-4.53%
PBM Psyence Biomedical	+5.26%	+17.28%	-29.20%	+79,999,900.00%	+79,999,900.00%

Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAV Camrova Resources	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NNN NNN REIT	3.7716 of 5 stars	1.1	4.0	4.2	1.8	2.4	1.7	1.9
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAV Camrova Resources	N/A	N/A	N/A	N/A
NNN NNN REIT	2.20	Hold	$44.50	8.46% Upside
PBM Psyence Biomedical	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAV Camrova Resources	C$7.51K	199.17	C$0.01 per share	10.00	C($0.04) per share	-1.86
NNN NNN REIT	$828.11M	9.06	$3.52 per share	11.67	$22.78 per share	1.80
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAV Camrova Resources	N/A	-C$0.03	N/A	∞	N/A	N/A	N/A	N/A	N/A
NNN NNN REIT	$392.34M	$2.16	19.00	12.07	4.76	47.38%	9.45%	4.64%	5/7/2024 (Estimated)
PBM Psyence Biomedical	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAV Camrova Resources	N/A	N/A	N/A	N/A	N/A
NNN NNN REIT	$2.26	5.51%	+10.53%	104.63%	34 Years
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A

Latest PBM, CON, CAV, and NNN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/15/2024	NNN NNN REIT	quarterly	$0.5650	5.54%	4/29/2024	4/30/2024	5/15/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAV Camrova Resources	N/A	0.01	0.01
NNN NNN REIT	1.05	1.26	1.26
PBM Psyence Biomedical	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
CAV Camrova Resources	N/A
NNN NNN REIT	89.96%
PBM Psyence Biomedical	77.44%

Insider Ownership

Company	Insider Ownership
CAV Camrova Resources	N/A
NNN NNN REIT	0.82%
PBM Psyence Biomedical	3.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CAV Camrova Resources	N/A	23.01 million	N/A	Not Optionable
NNN NNN REIT	82	182.85 million	181.35 million	Optionable
PBM Psyence Biomedical	N/A	8.79 million	8.47 million	N/A

PBM, CON, CAV, and NNN Headlines

Source	Headline
	Psyence Biomedical (NASDAQ:PBM) Shares Down 1.8% americanbankingnews.com - April 18 at 2:44 AM
	Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR) finance.yahoo.com - April 17 at 12:49 PM
	Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR) globenewswire.com - April 17 at 8:00 AM
	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial globenewswire.com - April 16 at 11:01 AM
	Psyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial tmcnet.com - April 8 at 12:13 PM
	Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial globenewswire.com - April 8 at 8:00 AM
	Psyence Group Inc.: Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business finanznachrichten.de - March 28 at 6:23 PM
	Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business globenewswire.com - March 26 at 11:06 AM
	Psyence Biomedical Ltd PBM morningstar.com - March 24 at 7:23 PM
	PBM Psyence Biomedical Ltd. seekingalpha.com - March 22 at 8:02 PM
	Psyence Biomedical Ltd (PBM) uk.investing.com - March 21 at 4:24 PM
	Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin stockhouse.com - March 18 at 7:19 PM
	Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin globenewswire.com - March 18 at 4:05 PM
	Psyence Biomedical faces Nasdaq delisting over market value uk.investing.com - March 17 at 3:36 PM
	Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares globenewswire.com - March 15 at 4:30 PM
	Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study globenewswire.com - March 12 at 11:15 AM
	Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones globenewswire.com - March 12 at 7:00 AM
	Psyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australia benzinga.com - March 11 at 7:54 PM
	Why Is Psyence Biomedical (PBM) Stock Up 90% Today? investorplace.com - March 8 at 6:17 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
Lockheed Martin Stock Aims for a Fresh All-Time High
April 23, 2024 9:59 AM
View Lockheed Martin Stock Aims for a Fresh All-Time High
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
March 27, 2024 7:30 AM
View Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
ASML’s Earnings Could Bring The Stock to New Highs
April 16, 2024 10:20 AM
View ASML’s Earnings Could Bring The Stock to New Highs
This Underrated Natural Gas Stock Could Rally Double-Digits Soon
April 1, 2024 9:15 AM
View This Underrated Natural Gas Stock Could Rally Double-Digits Soon

All Headlines

Company Descriptions

Camrova Resources

CVE:CAV

Camrova Resources Inc., a mining company, engages in the acquisition, exploration and development of resource properties. It owns a 7.23% interest in the Boleo copper-cobalt-zinc-manganese project located in Baja California Sur, Mexico. The company was formerly known as Baja Mining Corp. and changed its name to Camrova Resources Inc. in October 2016. Camrova Resources Inc. was incorporated in 1985 and is based in Vancouver, Canada.

NNN REIT

NYSE:NNN

NNN REIT invests primarily in high-quality retail properties subject generally to long-term, net leases. As of December 31, 2023, the company owned 3,532 properties in 49 states with a gross leasable area of approximately 36.0 million square feet and a weighted average remaining lease term of 10.1 years. NNN is one of only three publicly traded REITs to have increased annual dividends for 34 or more consecutive years.

Psyence Biomedical

NASDAQ:PBM

Newcourt Acquisition Corp is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. Newcourt Acquisition Corp is based in Oakland, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial